1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting - 01/22/2026
  1. Advisory Committee Calendar

Advisory Committee Meeting | Virtual

Event Title
January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting
January 22, 2026

Date:
January 22, 2026
Time:
9:00 a.m. - 4:30 p.m. ET

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

Online Viewing

Live Presentation

Agenda

On January 22, 2026, the Center for Tobacco Products’ TPSAC will meet virtually for an open session, during which the Committee will discuss modified risk tobacco product applications submitted by Swedish Match USA, Inc. for the following products, each available in two strengths (3 milligrams and 6 milligrams):  

  • ZYN Chill
  • ZYN Cinnamon
  • ZYN Citrus
  • ZYN Coffee
  • ZYN Cool Mint
  • ZYN Menthol
  • ZYN Peppermint
  • ZYN Smooth
  • ZYN Spearmint
  • ZYN Wintergreen

Discussion will focus on evidence related to the relative health risks of the products, consumer understanding and perceptions of the applicant’s proposed modified risk claim, and the potential public health impact of a modified risk marketing order.

Meeting Materials

FDA intends to make background material available to the public no later than two business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the time of the advisory committee meeting and posted on FDA’s website after the meeting.  

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.  

  • All electronic and written submissions may be submitted to docket number FDA-2025-N-0835 on or before January 21, 2026. Comments received on or before January 7, 2026, will be provided to the Committee.
  • Requests to make an oral presentation to be submitted to the contact person on or before 12 p.m. ET on December 31, 2025.
  • The contact person will notify interested persons regarding their request to speak by January 5, 2026.
  • Oral presentations from the public will be scheduled between 1:00 p.m. and 2:00 p.m. ET on January 22, 2026.

For more information about providing comments, orally or in writing, please see the Federal Register notice.

Contact Information

Rachel Jang, PharmD, Designated Federal Officer: 1-877-287-1373, TPSAC@fda.hhs.gov

FDA Advisory Committee Information Line: 1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the FDA's website and scroll down to the appropriate advisory committee meeting link or call the advisory committee information line to learn about possible modifications before coming to the meeting.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rachel Jang, PharmD, Designated Federal Officer at least 7 days in advance of the meeting.

Review the Federal Register notice about this meeting for additional details.  

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Back to Top